Cargando…
GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome
Epigenetic inactivation of GPX3 has been identified in various cancers including leukemia. Moreover, aberrant DNA methylation was also found as a dominant mechanism of disease progression in myelodysplastic syndrome (MDS). This study intended to explore GPX3 promoter methylation and its clinical rel...
Autores principales: | Zhou, Jing‐Dong, Lin, Jiang, Zhang, Ting‐Juan, Ma, Ji‐Chun, Yang, Lei, Wen, Xiang‐Mei, Guo, Hong, Yang, Jing, Deng, Zhao‐Qun, Qian, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5269561/ https://www.ncbi.nlm.nih.gov/pubmed/27891827 http://dx.doi.org/10.1002/cam4.984 |
Ejemplares similares
-
Abnormal expression and methylation of PRR34‐AS1 are associated with adverse outcomes in acute myeloid leukemia
por: Nan, Fang‐yu, et al.
Publicado: (2021) -
Disruption of erythroid nuclear opening and histone release in myelodysplastic syndromes
por: Zhao, Baobing, et al.
Publicado: (2019) -
DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia
por: Sun, Guo‐Kang, et al.
Publicado: (2019) -
Dihydroartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition
por: Yi, Renxin, et al.
Publicado: (2020) -
LC3A‐Positive “Stone‐Like” Structures Predict an Adverse Prognosis of Gastric Cancer
por: Liao, Wenjun, et al.
Publicado: (2014)